Nephrogram type. Days between first and second NCCT

Size: px
Start display at page:

Download "Nephrogram type. Days between first and second NCCT"

Transcription

1 Supplemental Table 1. Characteristics of patients with multiple unenhanced CT scans number Contrastenhanced procedure Pre-CE exam egfr present at first NCCT type Days between first and second NCCT present at second NCCT Negative patient outcome 1 Cath 52 Yes Cortical 4.4 No None 2 Cath 83 Yes Global/Focal 1.2 No None 3 Cath 36 Yes Global 12.6 No None 4 Cath 41 Yes Cortical 8.4 No AKI 5 Cath 18 Yes Global 5.5 No AKI, dialysis 6 Cath 43 No No AKI, dialysis 7 Cath 28 No No None 8 Cath 37 No No None 9 Cath 72 No No None 10 CECT 68 Yes Cortical 4.6 No AKI, dialysis, died 11 CECT 65 No No None 12 CECT 57 No No None 13 CECT 61 No No None 14 CECT 102 No No None 15 CECT 73 No No AKI, dialysis

2 Supplemental Table 2. Characteristics of patients and procedures with and without faint to moderate bilateral global nephrograms (HU>55) * No Number 28 (25%) 82 Age (median, IQR) 75 (62-80) 70 (56-77) 1.03 ( ).07 Female (%) 16 (57%) 38 (46%) 1.54 ( ).38 Diabetes mellitus 4 (14%) 4 (4.9%) 3.25 ( ).20 Chronic kidney disease 13 (46%) 23 (28%) 2.22 ( ).10 Nephrectomy or atrophic kidney 2 (7.1%) 3 (3.7%) 2.03 ( ).44 Kidney transplant 1 (3.6%) 4 (4.9%) 0.72 ( ).99 Acute kidney injury (history of) 0 4 (4.9%) -.57 Acute kidney injury 2 (7.1%) 5 (6.1%) 1.18 ( ).99 Acute hypotension/shock 8 (29%) 9 (11%) 3.24 ( ).0357 Pre- egfr 51 (33-68) 70 (56-91) 0.97 ( ) <.001 Pre- egfr subgroups > 60 ml/min/1.73 m 2 9 (32%) 56 (68%) ml/min/1.73 m 2 16 (57%) 23 (28%) < 30 ml/min/1.73 m 2 3 (11%) 3 (3.7%) CT 12 (22%) 43 (78%) 0.68 ( ).51** Cardiac catheterization 16 (29%) 39 (71%) Diagnostic catheterization 5 (17%) 25 (83%) 3.93 ( ).04*** Interventional catheterization 11 (44%) 14 (56%) Contrast dose (g I/kg) 0.43 ( ) 0.43 ( ) 0.70 ( ).75 **Comparing nephrogram proportions between CT versus catheterization recipients. ***Comparing nephrogram proportions between interventional versus diagnostic catheterization recipients.

3 Supplemental Table 3. Characteristics of patients and procedures with and without moderate to marked bilateral global nephrograms (HU>100) * No Number 6 (5.5%) 104 Age (median, IQR) 77 (70-80) 71 (57-78) 1.04 ( ).23 Female (%) 2 (33%) 52 (50%) 0.50 ( ).68 Diabetes mellitus 0 8 (7.7%) -.99 Chronic kidney disease 2 (33%) 34 (33%) 1.03 ( ).99 Nephrectomy or atrophic kidney 1 (17%) 4 (3.9%) 5.00 ( ).25 Kidney transplant 0 5 (4.8%) -.99 Acute kidney injury (history of) 0 4 (3.9%) -.99 Acute kidney injury 0 7 (6.7%) -.99 Acute hypotension/shock 3 (50%) 14 (13%) 6.43 ( ).05 Pre- egfr 60 (30-75) 65 (50-86) 0.98 ( ).30 Pre- egfr subgroups -.46 > 60 ml/min/1.73 m 2 3 (50%) 62 (60%) ml/min/1.73 m 2 2 (33%) 37 (36%) < 30 ml/min/1.73 m 2 1 (17%) 5 (4.8%) CT 2 (3.6%) 53 (96%) 0.48 ( ).68** Cardiac catheterization 4 (7.3%) 51 (93%) Diagnostic catheterization 1 (3.3%) 29 (97%) 3.95 ( ).32*** Interventional catheterization 3 (12%) 22 (88%) Contrast dose (g I/kg) 0.49 ( ) 0.43 ( ) 9.18 ( ).30 **Comparing nephrogram proportions between CT versus catheterization recipients. ***Comparing nephrogram proportions between interventional versus diagnostic catheterization recipients.

4 Supplemental Table 4. Characteristics of patients and procedures with and without bilateral global nephrograms following CECT * No Number 19 (32%) 41 Odds Ratio (95% CI) Age (median, IQR) 68 (54-75) 68 (54-75) 1.03 ( ).18 Female (%) 10 (53%) 20 (49%) 1.17 ( ).99 Diabetes mellitus 3 (16%) 2 (4.9%) 3.65 ( ).31 Chronic kidney disease 10 (53%) 9 (22%) 3.95 ( ).03 Nephrectomy or atrophic kidney 0 1 (2.4%) -.99 Kidney transplant 0 2 (4.9%) -.99 Acute kidney injury (history of) 0 2 (4.9%) -.99 Acute kidney injury 2 (11%) 2 (4.9%) 2.29 ( ).58 Acute hypotension/shock 5 (26%) 4 (9.8%) 3.30 ( ).13 Pre- egfr 65 (49-85) 78 (64-100) 0.98 ( ).04 Contrast dose (g I/kg) 0.44 ( ) 0.45 ( ) 0.10 (0-34.4).40

5 Supplemental Table 5. Characteristics of patients and procedures with and without bilateral global nephrograms following cardiac catheterization * No Number 27 (43%) 36 Age (median, IQR) 79 (69-82) 70 (59-77) 1.06 ( ).01 Female (%) 17 (63%) 16 (44%) 2.13 ( ).20 Diabetes mellitus 2 (7.4%) 2 (5.6%) 1.36 ( ).99 Chronic kidney disease 10 (37%) 11 (31%) 1.34 ( ).60 Nephrectomy or atrophic kidney 1 (3.7%) 3 (8.3%) 0.42 ( ).63 Kidney transplant 0 3 (8.3%) -.25 Acute kidney injury (history of) 1 (3.7%) 2 (5.6%) 0.65 ( ).99 Acute kidney injury 2 (7.4%) 3 (8.3%) 0.88 ( ).99 Acute hypotension/shock 7 (26%) 3 (8.3%) 3.85 ( ).08 Pre- egfr 52 (35-67) 61 (50-79) 0.99 ( ).11 Diagnostic (vs. PCI) 9 (33%) 24 (67%) 0.25 ( ).01 Femoral (vs. radial) 23 (85%) 33 (92%) 0.52 ( ).42 LVEF (%) 50 (36-60) 60 (51-65) 0.97 ( ).04 Total fluoroscopy time 18 (8-29) 9 (5-23) 1.04 ( ).02 Contrast dose (g I/kg) 0.43 ( ) 0.22 ( ) 16.0 ( ).07

SAFETY IN THE CATH LAB How to Minimise Contrast Toxicity

SAFETY IN THE CATH LAB How to Minimise Contrast Toxicity SAFETY IN THE CATH LAB How to Minimise Contrast Toxicity Dr. Vijay Kunadian MBBS, MD, MRCP Senior Lecturer and Consultant Interventional Cardiologist Institute of Cellular Medicine, Faculty of Medical

More information

Correspondence should be addressed to Lantam Sonhaye;

Correspondence should be addressed to Lantam Sonhaye; Radiology Research and Practice Volume 2015, Article ID 805786, 4 pages http://dx.doi.org/10.1155/2015/805786 Research Article Intravenous Contrast Medium Administration for Computed Tomography Scan in

More information

HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD

HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD Disclosure Member of research group with policy of not accepting honorariums or other payments

More information

CTA in acute stroke assessment

CTA in acute stroke assessment CTA in acute stroke assessment Assumptions: It is more efficient to cancel an unnecessary CTA than to order a CTA after the fact It is more efficient to make 1 trip to the CT scanner Even if no LVO, CTA

More information

Zhao Y Y et al. Ann Intern Med 2012;156:

Zhao Y Y et al. Ann Intern Med 2012;156: Zhao Y Y et al. Ann Intern Med 2012;156:560-569 Introduction Fibrates are commonly prescribed to treat dyslipidemia An increase in serum creatinine level after use has been observed in randomized, placebocontrolled

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content James MT, Neesh P, Hemmelgarn BR, et al. Derivation and external validation of prediction models for advanced chronic kidney disease following acute kidney injury. JAMA. doi:10.1001/jama.2017.16326

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Valle JA, Tamez H, Abbott JD, et al. Contemporary use and trends in unprotected left main coronary artery percutaneous coronary intervention in the United States: an analysis

More information

Enhancing Clinical Decision Support for Prevention of Contrast-Induced Acute Kidney Injury in Cardiac Catheterization

Enhancing Clinical Decision Support for Prevention of Contrast-Induced Acute Kidney Injury in Cardiac Catheterization Enhancing Clinical Decision Support for Prevention of Contrast-Induced Acute Kidney Injury in Cardiac Catheterization BACKGROUND The purpose of this project is to implement processes in all 3 cardiac catheterization

More information

Optimal Use of Iodinated Contrast Media In Oncology Patients. Focus on CI-AKI & cancer patient management

Optimal Use of Iodinated Contrast Media In Oncology Patients. Focus on CI-AKI & cancer patient management Optimal Use of Iodinated Contrast Media In Oncology Patients Focus on CI-AKI & cancer patient management Dr. Saritha Nair Manager-Medical Affairs-India & South Asia GE Healthcare Context Cancer patients

More information

Chapter 10. Cancer. ANZDATA gratefully acknowledges the contributions of the Cancer Working Group convened by Germaine Wong.

Chapter 10. Cancer. ANZDATA gratefully acknowledges the contributions of the Cancer Working Group convened by Germaine Wong. Chapter Cancer ANZDATA gratefully acknowledges the contributions of the Cancer Working Group convened by Germaine Wong Contents: Cancer -1 Incidence of Cancer on Renal Replacement Therapy -2 Kidney Cancer

More information

Chapter 10. Cancer. ANZDATA Registry 39th Annual Report. Data to 31-Dec-2015

Chapter 10. Cancer. ANZDATA Registry 39th Annual Report. Data to 31-Dec-2015 Chapter Cancer 216 ANZDATA Registry 39th Annual Report Data to 31-Dec-215 Incidence of Cancer on Renal Replacement Therapy Figures.1-.6 and table.1 show the cumulative incidence of non-skin cancer in patients

More information

Partial Nephrectomy: Does Ischemia Matter?

Partial Nephrectomy: Does Ischemia Matter? Partial Nephrectomy: Does Ischemia Matter? Karim Touijer, MD, MPH Attending Surgeon Memorial Sloan-Kettering Cancer Center Associate Professor of Urology Weill Cornell Medical College, New York No disclosures

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Downes KJ, Cowden C, Laskin BL, et al. Association of acute kidney injury with concomitant vancomycin and piperacillin/tazobactam treatment among hospitalized children. JAMA

More information

Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York

Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York 4th International Conference on Nephrology & Therapeutics September 14, 2015 Baltimore,

More information

Persistent CT nephrograms following cardiac catheterisation and intervention: initial observations

Persistent CT nephrograms following cardiac catheterisation and intervention: initial observations Insights Imaging (2012) 3:49 60 DOI 10.1007/s13244-011-0131-2 ORIGINAL ARTICLE Persistent CT nephrograms following cardiac catheterisation and intervention: initial observations Richard W. Katzberg & Wayne

More information

egfr > 50 (n = 13,916)

egfr > 50 (n = 13,916) Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according

More information

Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study

Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study Xin Zheng, MD, PhD; Jeptha P. Curtis, MD; Shuang Hu, PhD; YongfeiWang,

More information

Coronary Artery Bypass Grafting in Diabetics: All Arterial or Hybrid?

Coronary Artery Bypass Grafting in Diabetics: All Arterial or Hybrid? Coronary Artery Bypass Grafting in Diabetics: All Arterial or Hybrid? Dr. Daniel Navia M.D. Chief Cardiac Surgery Department ICBA, Buenos Aires Argentina, 2018 No disclosures 2 Current evidence The FREEDOM

More information

A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS

A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in Patients with Non-ST Elevation ACS Angioplasty to Blunt the rise Of troponin in Acute coronary syndromes Randomized for an immediate or Delayed intervention A Multicenter Randomized Trial of Immediate Versus Delayed Invasive Strategy in

More information

BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy

BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent

More information

A Paradigm Shift in Contrast-Induced Acute Kidney Injury (CI-AKI) Prevention

A Paradigm Shift in Contrast-Induced Acute Kidney Injury (CI-AKI) Prevention CE Mark US: Investigational device. Limited by Federal Law to investigational use only. A Paradigm Shift in Contrast-Induced Acute Kidney Injury (CI-AKI) Prevention 1 ED00092 Rev. A Clinical Problem 2

More information

Contrast-Induced Nephropathy: Evidenced Based Prevention

Contrast-Induced Nephropathy: Evidenced Based Prevention Contrast-Induced Nephropathy: Evidenced Based Prevention Michael J Cowley, MD, FSCAI Nothing to disclose Contrast-Induced Nephropathy (CIN) Definitions New onset or worsening of renal function after contrast

More information

CT and Contrast-Induced Nephrophathy (CIN)

CT and Contrast-Induced Nephrophathy (CIN) CT and Contrast-Induced Nephrophathy (CIN) Philipp A Kaufmann, MD Professor and Director of Cardiac Imaging University Hospital Zurich, Switzerland DISCLOSURE: Institutional Research contract with GE CIN

More information

ATTENDING PHYSICIAN'S STATEMENT KIDNEY FAILURE / SURGICAL REMOVAL OF ONE KIDNEY OR CHRONIC KIDNEY DISEASE

ATTENDING PHYSICIAN'S STATEMENT KIDNEY FAILURE / SURGICAL REMOVAL OF ONE KIDNEY OR CHRONIC KIDNEY DISEASE ATTENDING PHYSICIAN'S STATEMENT KIDNEY FAILURE / SURGICAL REMOVAL OF ONE KIDNEY OR CHRONIC KIDNEY DISEASE A) Patient s Particulars Name of Patient Gender NRIC/FIN or Passport No. Date of Birth (ddmmyyyy)

More information

Neurologic complications after transradial or transfemoral approach for diagnostic and interventional cardiac catheterization.

Neurologic complications after transradial or transfemoral approach for diagnostic and interventional cardiac catheterization. Neurologic complications after transradial or transfemoral approach for diagnostic and interventional cardiac catheterization Dr Paolo Buja Trend Patients undergoing PCI in UK FEMORAL RADIAL Ratib JACC

More information

Secular Trends in Cardiovascular Disease in Kidney Transplant Recipients: 1994 to 2009

Secular Trends in Cardiovascular Disease in Kidney Transplant Recipients: 1994 to 2009 Western University Scholarship@Western Electronic Thesis and Dissertation Repository June 2015 Secular Trends in Cardiovascular Disease in Kidney Transplant Recipients: 1994 to 2009 Ngan Lam The University

More information

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography

Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Statin therapy in patients with Mild to Moderate Coronary Stenosis by 64-slice Multidetector Coronary Computed Tomography Hyo Eun Park 1, Eun-Ju Chun 2, Sang-Il Choi 2, Soyeon Ahn 2, Hyung-Kwan Kim 3,

More information

KDOQI Guidelines. Overview. Predicting Successful Fistula Maturation Warren Gasper MD UCSF Vascular Surgery Fellow 2011 UCSF Vascular Symposium

KDOQI Guidelines. Overview. Predicting Successful Fistula Maturation Warren Gasper MD UCSF Vascular Surgery Fellow 2011 UCSF Vascular Symposium DISCLOSURES: NONE Predicting Successful Fistula Maturation Warren Gasper MD UCSF Vascular Surgery Fellow 2011 UCSF Vascular Symposium KDOQI Guidelines AV fistulas have better outcomes than grafts or catheters

More information

Introduction. Soe Ko, 1 Sudharsan Venkatesan, 1 Kushma Nand, 1,2 Vicki Levidiotis, 2,3 Craig Nelson 2,3 and Edward Janus 1,3.

Introduction. Soe Ko, 1 Sudharsan Venkatesan, 1 Kushma Nand, 1,2 Vicki Levidiotis, 2,3 Craig Nelson 2,3 and Edward Janus 1,3. doi:10.1111/imj.13729 International statistical classification of diseases and related health problems coding underestimates the incidence and prevalence of acute kidney injury and chronic kidney disease

More information

Heart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France

Heart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France Heart Failure Guillaume Jondeau Hôpital Bichat, Paris, France Epidemiology Importance of PEF Europe I-PREFER study. Abstract: 2835 Prevalence of HF Preserved LV systolic Function older (65 vs 62 y, p

More information

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)

ALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage

More information

CT Renal 3 Phase + Pelvis CT Abdomen Pelvis WO W - NC.A.V, Pelvis during V

CT Renal 3 Phase + Pelvis CT Abdomen Pelvis WO W - NC.A.V, Pelvis during V CT Renal 3 Phase + Pelvis CT Abdomen Pelvis WO W - NC.A.V, Pelvis during V Reviewed By: Anna Ellermeier, MD; Brett Mollard, MD Last Reviewed: August 2018 Contact: (866) 761-4200, Option 1 In accordance

More information

Faculty/Presenter Disclosure

Faculty/Presenter Disclosure Faculty/Presenter Disclosure Faculty: Andre Lamy Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria: None Consulting Fees: None Other: None CORONARY: The Coronary

More information

ΓΙΑΚΔΡΚΙΓΙΚΗ ΠΡΟΠΔΛΑΗ ΚΑΙ ΑΓΓΔΙΟΠΛΑΣΙΚΗ: ΤΜΒΟΤΛΔ ΚΑΙ ΜΤΣΙΚΑ

ΓΙΑΚΔΡΚΙΓΙΚΗ ΠΡΟΠΔΛΑΗ ΚΑΙ ΑΓΓΔΙΟΠΛΑΣΙΚΗ: ΤΜΒΟΤΛΔ ΚΑΙ ΜΤΣΙΚΑ ΓΙΑΚΔΡΚΙΓΙΚΗ ΠΡΟΠΔΛΑΗ ΚΑΙ ΑΓΓΔΙΟΠΛΑΣΙΚΗ: ΤΜΒΟΤΛΔ ΚΑΙ ΜΤΣΙΚΑ ΓΙΔΝΔΡΓΔΙΑ ΠΡΩΣΟΓΔΝΟΤ ΓΙΑΓΔΡΜΙΚΗ ΣΔΦΑΝΙΑΙΑ ΠΑΡΔΜΒΑΗ ΑΠΟ ΣΗΝ ΚΔΡΚΙΓΙΚΗ ΑΡΣΗΡΙΑ Λάμπρος Κ. Μόσιαλος Γιεσθσντής Δπεμβατικός Καρδιολόγος ΓΝΘ «Παπαγεωργίοσ»

More information

and Treatment in Emergency Care) Trial: Intravenous Glucose, Insulin & Potassium (GIK) in Emergency Medical Services

and Treatment in Emergency Care) Trial: Intravenous Glucose, Insulin & Potassium (GIK) in Emergency Medical Services Results of the IMMEDIATE (Immediate Myocardial Metabolic Enhancement DuringInitial Assessment and Treatment in Emergency Care) Trial: A Double Blinded Randomized Controlled Trial of Intravenous Glucose,

More information

TRANSRADIAL CARDIAC CATHETERIZATION. Amanda Ryan, DO, Interventional Cardiologist Heart Care Centers of Florida April 13, 2013

TRANSRADIAL CARDIAC CATHETERIZATION. Amanda Ryan, DO, Interventional Cardiologist Heart Care Centers of Florida April 13, 2013 TRANSRADIAL CARDIAC CATHETERIZATION Amanda Ryan, DO, Interventional Cardiologist Heart Care Centers of Florida April 13, 2013 TOPICS Historical perspective and current trends Rationale Bleeding for the

More information

Bifurcation stenting with BVS

Bifurcation stenting with BVS Bifurcation stenting with BVS Breaking the limits or just breaking the struts? Maciej Lesiak Department of Cardiology University Hospital in Poznan, Poland Disclosure Speaker s name: Maciej Lesiak I have

More information

RENAL TRANSPLANT PATIENTS WITH HIGH-FLOW AVF: WHEN & HOW TO INTERVENE Stuart Greenstein, MD Abdominal Organ Transplant Division Albert Einstein

RENAL TRANSPLANT PATIENTS WITH HIGH-FLOW AVF: WHEN & HOW TO INTERVENE Stuart Greenstein, MD Abdominal Organ Transplant Division Albert Einstein RENAL TRANSPLANT PATIENTS WITH HIGH-FLOW AVF: WHEN & HOW TO INTERVENE Stuart Greenstein, MD Abdominal Organ Transplant Division Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY

More information

Effects of Lowering LDL Cholesterol on Progression of Kidney Disease

Effects of Lowering LDL Cholesterol on Progression of Kidney Disease Effects of Lowering LDL Cholesterol on Progression of Kidney Disease Richard Haynes, David Lewis, Jonathan Emberson, Christina Reith, Lawrence Agodoa, Alan Cass, Jonathan C. Craig, Dick de Zeeuw, Bo Feldt-Rasmussen,

More information

Cardiac surgery and acute kidney injury: retrospective study

Cardiac surgery and acute kidney injury: retrospective study Cardiac surgery and acute kidney injury: retrospective study Department of Cardiovascular and Thoracic Surgery University of Liege Hospital (ULg CHU), Belgium MG LAGNY 1, F BLAFFART 1, JO DEFRAIGNE 2,

More information

Primary causes: Complement dysregulation (50% of non-shiga toxin-producing E. coli ) Secondary causes:

Primary causes: Complement dysregulation (50% of non-shiga toxin-producing E. coli ) Secondary causes: General department INTRODUCTION The hemolytic uremic syndrome (HUS): microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury One of the main causes of acute kidney injury in children

More information

Decrease cost of inpatient stay Decrease bed diversions Improve bed utilization (Interqual Criteria) Patient Satisfaction Reduce patient costs

Decrease cost of inpatient stay Decrease bed diversions Improve bed utilization (Interqual Criteria) Patient Satisfaction Reduce patient costs Decrease cost of inpatient stay Decrease bed diversions Improve bed utilization (Interqual Criteria) Patient Satisfaction Reduce patient costs (family hotel, drive back to the VA for next day pick up)

More information

Las dos caras de la cretinina sérica The two sides of serum creatinine

Las dos caras de la cretinina sérica The two sides of serum creatinine Las dos caras de la cretinina sérica The two sides of serum creatinine ASOCIACION COSTARRICENSE DE MEDICINA INTERNA San José, Costa Rica June 2017 Kianoush B. Kashani, MD, MSc, FASN, FCCP 2013 MFMER 3322132-1

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Smith D, Chudgar A, Daly B, Cooper M. Evaluation of potential renal transplant recipients with computed tomography angiography. Arch Intern Med. doi: 10.1001/archsurg.2012.1466.

More information

Measure #167 (NQF 0114): Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure National Quality Strategy Domain: Effective Clinical Care

Measure #167 (NQF 0114): Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure National Quality Strategy Domain: Effective Clinical Care Measure #167 (NQF 0114): Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE

More information

Transradial vs. Transfemoral Access in STEMI: Should We Randomize?

Transradial vs. Transfemoral Access in STEMI: Should We Randomize? Transradial vs. Transfemoral Access in STEMI: Should We Randomize? Ajay J. Kirtane, MD, SM Center for Interventional Vascular Therapy Columbia University Medical Center / New York Presbyterian Hospital

More information

Radial Artery Access Improving Outcomes and Decreasing Costs

Radial Artery Access Improving Outcomes and Decreasing Costs Howard A. Cohen, MD, FACC, FSCAI Director, Division of Cardiac Intervention Co-Director, Cardiac Catheterization Laboratories Lenox Hill Heart & Vascular Institute Institute DISCLOSURE Nothing to disclose

More information

Supplemental Material

Supplemental Material Supplemental Material Supplemental Results The baseline patient characteristics for all subgroups analyzed are shown in Table S1. Tables S2-S6 demonstrate the association between ECG metrics and cardiovascular

More information

Online Appendix (JACC )

Online Appendix (JACC ) Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis

More information

Version 4.4. Institutional Outcomes Report 2014Q3. National Outcomes Report Aggregation Date: Jan 12, :59:59 PM

Version 4.4. Institutional Outcomes Report 2014Q3. National Outcomes Report Aggregation Date: Jan 12, :59:59 PM Version 4.4 Institutional Outcomes Report 2014Q3 National Outcomes Report 999997 Aggregation Date: Jan 12, 2015 11:59:59 PM Publish Date: Jan 29, 2015 If User desires to publish or otherwise distribute

More information

Survival of End Stage Renal Failure Patients with Cancer

Survival of End Stage Renal Failure Patients with Cancer Survival of End Stage Renal Failure Patients with Cancer Angela Webster Centre for Kidney Research, The Children s Hospital at Westmead Department of Renal Medicine, Westmead Hospital, NSW School of Public

More information

Assessment of estimated GFR and clinical predictors of contrast induced nephropathy among diabetic patients undergoing cardiac catheterization

Assessment of estimated GFR and clinical predictors of contrast induced nephropathy among diabetic patients undergoing cardiac catheterization The Egyptian Heart Journal (2015) 67, 249 258 HOSTED BY Egyptian Society of Cardiology The Egyptian Heart Journal www.elsevier.com/locate/ehj www.sciencedirect.com ORIGINAL ARTICLE Assessment of estimated

More information

Chronic Kidney Disease. Dr Mohan B. Biyani A. Professor of Medicine University of Ottawa/Ottawa Hospital

Chronic Kidney Disease. Dr Mohan B. Biyani A. Professor of Medicine University of Ottawa/Ottawa Hospital Chronic Kidney Disease Dr Mohan B. Biyani A. Professor of Medicine University of Ottawa/Ottawa Hospital Health Seminar Series Date 12 May 2013 Objectives Normal functioning of Kidneys. Risk factors to

More information

ADVANCE post trial ObservatioNal Study

ADVANCE post trial ObservatioNal Study Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Irish AB, Viecelli AK, Hawley CM, et al; for the Omega-3 Fatty Acids (Fish Oils) and Aspirin in Vascular Access Outcomes in Renal Disease (FAVOURED) Study Collaborative Group.

More information

Patient characteristics Intervention Comparison Length of followup

Patient characteristics Intervention Comparison Length of followup ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing

More information

Concept and General Objectives of the Conference: Prognosis Matters. Andrew S. Levey, MD Tufts Medical Center Boston, MA

Concept and General Objectives of the Conference: Prognosis Matters. Andrew S. Levey, MD Tufts Medical Center Boston, MA Concept and General Objectives of the Conference: Prognosis Matters Andrew S. Levey, MD Tufts Medical Center Boston, MA General Objectives Topics to discuss What are the key outcomes of CKD? What progress

More information

EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017

EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts

More information

Case 1 Organ Set 3. Case 1 (for Organ Sets 1 3) 10/2/2015 CARIOVASCULAR II LABORATORY

Case 1 Organ Set 3. Case 1 (for Organ Sets 1 3) 10/2/2015 CARIOVASCULAR II LABORATORY MHD I CRIOVSCULR II LORTORY 0/5/5 Case Organ Set Organ Set 2 Organ Set 3 Case (for Organ Sets 3) 72 year old man with a history of diabetes mellitus type 2, HTN, and hyperlipidemia presents with progressive

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Diagnostics Assessment Programme

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Diagnostics Assessment Programme NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Diagnostics Assessment Programme Point-of-care creatinine tests to assess kidney function before administering intravenous contrast for computed tomography

More information

Older Living Kidney Donors and Recipients. Charles Le University of Colorado 6/24/11

Older Living Kidney Donors and Recipients. Charles Le University of Colorado 6/24/11 Older Living Kidney Donors and Recipients Charles Le University of Colorado 6/24/11 Clinical Scenario HPI: 60 y/o healthy AAM with h/o CKD5 on HD x 2 yrs 2/2 HTN, was evaluated in transplant clinic for

More information

Long-term Non-ESRD Kidney Donor Risks. Arthur Matas Dept Surgery University of Minnesota

Long-term Non-ESRD Kidney Donor Risks. Arthur Matas Dept Surgery University of Minnesota Long-term Non-ESRD Kidney Donor Risks Arthur Matas Dept Surgery University of Minnesota Conflict of Interest Disclosure I have no relevant financial relationships to disclose No off label use will be discussed

More information

Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies

Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies Mohammad Zubaid, MB, ChB, FRCPC, FACC Professor of Medicine, Kuwait University Chairman, Faculty of Cardiology,

More information

The PRESERVE trial: does it guide prevention strategies for post angiography acute kidney injury?

The PRESERVE trial: does it guide prevention strategies for post angiography acute kidney injury? Editorial Page 1 of 7 The PRESERVE trial: does it guide prevention strategies for post angiography acute kidney injury? Richard Solomon Larner College of Medicine, University of Vermont, Burlington, VT,

More information

Effect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF)

Effect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF) Effect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF) Piotr Ponikowski, Dirk J. van Veldhuisen, Josep Comin-Colet Georg Ertl, Michel Komajda,

More information

Immediate Normalisation of Blood Pressure following Intervention in Functional Total Occlusion of Unilateral Renal Artery with an Atrophic Kidney

Immediate Normalisation of Blood Pressure following Intervention in Functional Total Occlusion of Unilateral Renal Artery with an Atrophic Kidney Immediate Normalisation of Blood Pressure following Intervention in Functional Total Occlusion of Unilateral Renal Artery with an Atrophic Kidney Dr Parminder Singh Otaal Assistant Professor Department

More information

Uroradiology For Medical Students

Uroradiology For Medical Students Uroradiology For Medical Students Lesson 8 Computerized Tomography 2 American Urological Association Objectives In this lesson you will: Gain more experience reading CT images Learn how computer generated

More information

High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial

High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2018 High-Sensitive Troponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS): a stepped-wedge cluster-randomised controlled trial Professor

More information

Safety of contrast agents CT / MR / Echo

Safety of contrast agents CT / MR / Echo International Conference on Integrated Medical Imaging in Cardiovascular Diseases (IMIC 2013, IAEA) Safety of contrast agents CT / MR / Echo Philipp A Kaufmann, MD Professor and Director of Cardiac Imaging

More information

Who and When to Refer for a Heart Transplant

Who and When to Refer for a Heart Transplant Who and When to Refer for a Heart Transplant Dr Jayan Parameshwar Consultant Cardiologist Papworth Hospital BSH 24 th November 2017 BSH Annual Autumn Meeting 2017 Presentation title: Who and when to refer

More information

Effect of Aliskiren on Postdischarge Outcomes Among Non-Diabetic Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Outcomes Trial

Effect of Aliskiren on Postdischarge Outcomes Among Non-Diabetic Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Outcomes Trial Effect of Aliskiren on Postdischarge Outcomes Among Non-Diabetic Patients Hospitalized for Heart Failure: Insights from the ASTRONAUT Outcomes Trial Aldo P. Maggioni, MD, FESC Associazione Nazionale Medici

More information

Who? Dialysis for Acute Renal Failure: Who, What, How, and When? Kathleen D. Liu, MD, PhD, MAS June 2011

Who? Dialysis for Acute Renal Failure: Who, What, How, and When? Kathleen D. Liu, MD, PhD, MAS June 2011 Dialysis for Acute Renal Failure: Who, What, How, and When? Kathleen D. Liu, MD, PhD, MAS June 2011 Dorre Nicholau MD PhD Clinical Professor Department of Anesthesia and Perioperative Care University of

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney

More information

Thanks to our Speakers!

Thanks to our Speakers! Thanks to our Speakers! Fizza Naqvi, MD Assistant Professor at the Department of Medicine (Nephrology), Johns Hopkins Attending physician at Johns Hopkins hospital. Involved with kidney recipient evaluation

More information

Pieter Stella, MD, PhD

Pieter Stella, MD, PhD A Permanent Polymer Zotarolimus-eluting Stent versus a Polymer-Free Amphilimus-eluting Stent in all-comers; Results of the ReCre8 Trial Pieter Stella, MD, PhD On behalf of the ReCre8 Study investigators

More information

Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality

Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality Shannon H. Norris, BSN, RN June 6, 2018 Dialysis Initiation and Optimal Vascular Access: Outcomes and Mortality DISCUSSION: End Stage

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Outcome High Priority Quality ID #167 (NQF 0114): Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Preventable Healthcare Harm

More information

Chapter 7. Australian Waiting List. ANZDATA Registry 39th Annual Report. Data to 31-Dec-2015

Chapter 7. Australian Waiting List. ANZDATA Registry 39th Annual Report. Data to 31-Dec-2015 Chapter 7 Australian Waiting List 216 ANZDATA Registry 39th Annual Report Data to 31-Dec-215 Stock and Flow The waiting list data reported here are derived from the Australian National Organ Matching System

More information

The patient with 30 min chest pain presenting at the ER two hours after onset of symptoms. Professor Christian Mueller

The patient with 30 min chest pain presenting at the ER two hours after onset of symptoms. Professor Christian Mueller The patient with 30 min chest pain presenting at the ER two hours after onset of symptoms Professor Christian Mueller Disclosures Swiss National Science Foundation.... Research support / travel support

More information

Cardiothoracic Department October 9, Deborah Winters, RN BSN Clinical Excellence

Cardiothoracic Department October 9, Deborah Winters, RN BSN Clinical Excellence Cardiothoracic Department October 9, 2013 Deborah Winters, RN BSN Clinical Excellence Quarterly Executive Summary CathPCI Registry PCI Performance Measures PCI Process/Outcome Metrics Diagnostic Cath Process/Outcome

More information

Dashboard and Outcomes Report with Case Studies

Dashboard and Outcomes Report with Case Studies Dashboard and Outcomes Report with Case Studies Kim Hustler Clinical Quality Consultant, American College of Cardiology The following relationships exist: Kim Hustler: No Disclosures Section F- Procedures

More information

Contrast Induced Nephropathy

Contrast Induced Nephropathy Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)

More information

Update in. Acute Kidney Injury. Mark Devonald Consultant Nephrologist. Nottingham AKI Research Group

Update in. Acute Kidney Injury. Mark Devonald Consultant Nephrologist. Nottingham AKI Research Group Update in Acute Kidney Injury Mark Devonald Consultant Nephrologist If you stay awake you might hear about Why AKI is important Some cases to illustrate some specific points A couple of updates on AKI

More information

SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart.

SUPPLEMENTARY DATA. Supplementary Figure S1. Cohort definition flow chart. Supplementary Figure S1. Cohort definition flow chart. Supplementary Table S1. Baseline characteristics of study population grouped according to having developed incident CKD during the follow-up or not

More information

Systolic Blood Pressure Intervention Trial (SPRINT)

Systolic Blood Pressure Intervention Trial (SPRINT) 09:30-09:50 2016.4.15 Systolic Blood Pressure Intervention Trial (SPRINT) IN A NEPHROLOGIST S VIEW Sejoong Kim Seoul National University Bundang Hospital Current guidelines for BP control Lowering BP

More information

Downloaded from:

Downloaded from: Annemans, L; Danchin, N; Van de Werf, F; Pocock, S; Licour, M; Medina, J; Bueno, H (2016) Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis

More information

Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC

Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical

More information

Administration of Gadolinium Contrast in Adults Procedural Guideline

Administration of Gadolinium Contrast in Adults Procedural Guideline Administration of Gadolinium Contrast in Adults Procedural Guideline This procedural guideline is designed to assist Radiologists by providing an analytical framework for the evaluation of gadolinium contrast

More information

STEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia.

STEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia. STEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia. PART 1 Systems of care for STEMI. STEMI Management Coronary angiogram +/- stenting. Prehospital thrombolysis

More information

2015 Children's Mercy Hospitals and Clinics. All Rights Reserved.

2015 Children's Mercy Hospitals and Clinics. All Rights Reserved. Growth van Stralen KJ, et al., Kidney Int, 2014 Blood Pressure Management van Stralen KJ, et al., Kidney Int, 2014 Sodium Losses on PD Infants might need higher UF rate per BSA as compared to adults to

More information

SITA 100 mg (n = 378)

SITA 100 mg (n = 378) Supplementary Table 1. Summary of Sulfonylurea Background Therapy at Baseline and During the Treatment Period. Sulfonylurea at baseline, n (%) SITA 100 mg (n = 378) CANA 300 mg (n = 377) Total (N = 755)

More information

Renal and ureteral involvement in Erdheim-Chester disease: analysis of a single centre cohort

Renal and ureteral involvement in Erdheim-Chester disease: analysis of a single centre cohort Renal and ureteral involvement in Erdheim-Chester disease: analysis of a single centre cohort Gaia Manari, Davide Gianfreda, Andrea Posteraro, Alessandro A. Palumbo and Augusto Vaglio Nephrology Unit and

More information

Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia

Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia Supplementary Table S1 International Classification of Disease 10 (ICD-10) codes Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care I48 AF

More information

CT Pancreas 3 Phase CT Abdomen WO W - NC.A.V

CT Pancreas 3 Phase CT Abdomen WO W - NC.A.V CT Pancreas 3 Phase CT Abdomen WO W - NC.A.V Reviewed By: Rachael Edwards, MD; Anna Ellermeier, MD; Brett Mollard, MD Last Reviewed: January 2019 Contact: (866) 761-4200, Option 1 In accordance with the

More information

New Technologies for Cardiac CT. Geoffrey D. Rubin, MD, MBA, FACR, FNASCI Duke University

New Technologies for Cardiac CT. Geoffrey D. Rubin, MD, MBA, FACR, FNASCI Duke University 1996 New Technologies for Cardiac CT Geoffrey D. Rubin, MD, MBA, FACR, FNASCI Duke University New Technology The Long View Levels of Efficacy Endpoint Examples 1: Technical Imaging resolution 2: Diagnostic

More information

Supplement materials:

Supplement materials: Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction

More information

Jun-Won Lee, Sang Wook Park, Jung-Woo Son, Young Jin Youn, Min-Soo Ahn, Sung Gyun Ahn, Jang-Young Kim, Byung-Soo Yoo, Junghan Yoon, Seung-Hwan Lee

Jun-Won Lee, Sang Wook Park, Jung-Woo Son, Young Jin Youn, Min-Soo Ahn, Sung Gyun Ahn, Jang-Young Kim, Byung-Soo Yoo, Junghan Yoon, Seung-Hwan Lee The procedural success and complication rate of the left distal radial approach for coronary angiography and percutaneous coronary intervention. Prospective observational study (LeDRA) Jun-Won Lee, Sang

More information

Changing Demographics in Death After Devastating Brain Injury

Changing Demographics in Death After Devastating Brain Injury Changing Demographics in Death After Devastating Brain Injury Andreas H. Kramer MD MSc FRCPC Departments of Critical Care Medicine & Clinical Neurosciences Foothills Medical Center, University of Calgary

More information

A patient with acute heart failure and renal impairment ACCA Masterclass 2017

A patient with acute heart failure and renal impairment ACCA Masterclass 2017 A patient with acute heart failure and renal impairment Dr Sofie Gevaert Mister P. J.M., 67-years-old Cardiac risk factors: Ex-smoker, AHT, Type 2 diabetes, BMI 43, Hyperlipidaemia Medical history: 2009:

More information